Kura Oncology to Report First Quarter 2025 Financial Results
Kura Oncology (KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has scheduled its first quarter 2025 financial results announcement. The company will release its Q1 2025 results after U.S. market close on Thursday, May 1, 2025.
Management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss financial performance and provide a corporate update. Investors can access the live call via phone using the numbers (800) 245-3047 (domestic) or (203) 518-9765 (international) with conference ID: KURAQ1. A live webcast and replay will be available through the investor relations section of Kura's website.
Kura Oncology (KURA), un'azienda biofarmaceutica in fase clinica specializzata in farmaci di precisione per il trattamento del cancro, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025. La società pubblicherà i risultati del Q1 2025 dopo la chiusura del mercato statunitense il giovedì 1 maggio 2025.
Il management terrà una webcast e una conference call alle 16:30 ET / 13:30 PT per discutere delle performance finanziarie e fornire un aggiornamento aziendale. Gli investitori potranno seguire la chiamata in diretta telefonicamente ai numeri (800) 245-3047 (nazionale) o (203) 518-9765 (internazionale) con ID conferenza: KURAQ1. Una webcast live e la registrazione saranno disponibili nella sezione investor relations del sito web di Kura.
Kura Oncology (KURA), una compañía biofarmacéutica en fase clínica centrada en medicamentos de precisión para el tratamiento del cáncer, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025. La empresa publicará sus resultados del Q1 2025 después del cierre del mercado estadounidense el jueves 1 de mayo de 2025.
La dirección realizará una webcast y una conferencia telefónica a las 4:30 p.m. ET / 1:30 p.m. PT para discutir el desempeño financiero y ofrecer una actualización corporativa. Los inversores podrán acceder a la llamada en vivo por teléfono usando los números (800) 245-3047 (nacional) o (203) 518-9765 (internacional) con ID de conferencia: KURAQ1. Una retransmisión en vivo y la grabación estarán disponibles en la sección de relaciones con inversores del sitio web de Kura.
Kura Oncology (KURA)는 암 치료를 위한 정밀 의약품에 중점을 둔 임상 단계의 생명공학 제약 회사로, 2025년 1분기 재무 실적 발표를 예정하고 있습니다. 회사는 2025년 5월 1일 목요일 미국 시장 마감 후 2025년 1분기 실적을 발표할 예정입니다.
경영진은 재무 성과를 논의하고 회사 현황을 업데이트하기 위해 오후 4:30 ET / 오후 1:30 PT에 웹캐스트와 컨퍼런스 콜을 진행합니다. 투자자는 (국내) (800) 245-3047 또는 (국제) (203) 518-9765 번호로 컨퍼런스 ID: KURAQ1을 사용해 실시간 통화에 참여할 수 있습니다. 웹캐스트 생중계와 재방송은 Kura 웹사이트의 투자자 관계 섹션에서 제공됩니다.
Kura Oncology (KURA), une entreprise biopharmaceutique en phase clinique spécialisée dans les médicaments de précision pour le traitement du cancer, a programmé l'annonce de ses résultats financiers du premier trimestre 2025. La société publiera ses résultats du T1 2025 après la clôture du marché américain le jeudi 1er mai 2025.
La direction tiendra une webdiffusion et une conférence téléphonique à 16h30 ET / 13h30 PT pour discuter des performances financières et fournir une mise à jour de l'entreprise. Les investisseurs pourront accéder à l'appel en direct par téléphone en composant les numéros (800) 245-3047 (national) ou (203) 518-9765 (international) avec l'ID de conférence : KURAQ1. Une webdiffusion en direct et un replay seront disponibles dans la section relations investisseurs du site web de Kura.
Kura Oncology (KURA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Präzisionsmedikamente zur Krebsbehandlung spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 geplant. Das Unternehmen wird die Ergebnisse für Q1 2025 nach Börsenschluss in den USA am Donnerstag, den 1. Mai 2025 veröffentlichen.
Das Management wird um 16:30 Uhr ET / 13:30 Uhr PT eine Webcast- und Telefonkonferenz abhalten, um die finanzielle Leistung zu besprechen und ein Unternehmensupdate zu geben. Investoren können den Live-Anruf telefonisch unter den Nummern (800) 245-3047 (national) oder (203) 518-9765 (international) mit der Konferenz-ID: KURAQ1 verfolgen. Ein Live-Webcast und eine Aufzeichnung sind im Investor-Relations-Bereich der Kura-Website verfügbar.
- None.
- None.
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2025 financial results after the close of U.S. financial markets on Thursday, May 1, 2025. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing (800) 245-3047 for domestic callers and (203) 518-9765 for international callers and entering the conference ID: KURAQ1. A live webcast and archived replay of the event will be available here or online from the investor relations section of the company website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates, designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food & Drug Administration for the treatment of relapsed/refractory (R/R) NPM1-mutant (NPM1-m) AML. In November 2024, Kura entered into a global strategic collaboration agreement with Kyowa Kirin to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-m AML has been completed, and in the second quarter of 2025, the companies announced submission of an NDA for ziftomenib for the treatment of adult patients with R/R NPM1-m AML. Kura and Kyowa Kirin are conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-m and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor (FTI), is being evaluated in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Contacts
Investors:
Patti Bank
Managing Director
(415) 513-1284
patti.bank@icrhealthcare.com
Media:
Alexandra Weingarten
Associate Director, Corporate Communications
& Investor Relations
(858) 500-8822
alexandra@kuraoncology.com
FAQ
When will Kura Oncology (KURA) release its Q1 2025 earnings?
How can investors join Kura Oncology's Q1 2025 earnings call?
What time is Kura Oncology's (KURA) Q1 2025 earnings call?
Where can I find the replay of KURA's Q1 2025 earnings webcast?
